(COR) Cencora - Overview
Sector: Healthcare | Industry: Medical Distribution | Exchange: NYSE (USA) | Market Cap: 52.407m USD | Total Return: -8.9% in 12m
Avg Turnover: 516M
EPS Trend: 99.8%
Qual. Beats: 0
Rev. Trend: 99.0%
Qual. Beats: -1
Warnings
Altman Z'' 0.41 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
Cencora, Inc. (COR), formerly AmerisourceBergen, is a global pharmaceutical distributor and provider of healthcare infrastructure services. The company operates through two primary segments: U.S. Healthcare Solutions and International Healthcare Solutions. Its core business involves the procurement and delivery of generic, injectable, and specialty pharmaceuticals, alongside vaccines and animal health products, to a diverse client base including hospitals, retail pharmacies, and medical clinics.
The company functions as a critical intermediary in the healthcare supply chain, operating within a highly consolidated industry where three major distributors control approximately 90% of the U.S. market. This business model relies on high-volume, low-margin distribution, supplemented by higher-margin value-added services such as clinical trial support, data analytics, and global logistics for biopharmaceutical manufacturers.
Investors can further evaluate the companys historical performance and valuation metrics on ValueRay. Founded in 1871 and headquartered in Pennsylvania, Cencora continues to expand its international footprint through specialized transportation and commercialization services tailored to the biopharmaceutical industry.
- Expansion of high-margin specialty pharmaceutical distribution drives overall revenue growth
- Rising demand for GLP-1 weight loss drugs boosts pharmaceutical sales volume
- Global supply chain efficiencies and generic drug pricing stabilize operational margins
- Regulatory scrutiny of pharmacy benefit manager relationships threatens existing reimbursement models
- Strategic acquisitions in international healthcare markets diversify geographic revenue streams
| Net Income: 2.55b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -3.11 > 1.0 |
| NWC/Revenue: -0.91% < 20% (prev -2.19%; Δ 1.28% < -1%) |
| CFO/TA 0.03 > 3% & CFO 2.28b > Net Income 2.55b |
| Net Debt (10.1b) to EBITDA (4.10b): 2.48 < 3 |
| Current Ratio: 0.95 > 1.5 & < 3 |
| Outstanding Shares: last quarter (195.4m) vs 12m ago 0.15% < -2% |
| Gross Margin: 3.47% > 18% (prev 2.94%; Δ 0.52% > 0.5%) |
| Asset Turnover: 430.1% > 50% (prev 435.8%; Δ -5.68% > 0%) |
| Interest Coverage Ratio: 6.46 > 6 (EBIT TTM 3.06b / Interest Expense TTM 474.0m) |
| A: -0.04 (Total Current Assets 53.1b - Total Current Liabilities 56.1b) / Total Assets 81.7b |
| B: 0.10 (Retained Earnings 8.49b / Total Assets 81.7b) |
| C: 0.04 (EBIT TTM 3.06b / Avg Total Assets 76.4b) |
| D: 0.04 (Book Value of Equity 3.40b / Total Liabilities 78.1b) |
| Altman-Z'' = 0.41 = B |
| DSRI: 0.99 (Receivables 24.9b/23.7b, Revenue 329b/310b) |
| GMI: 0.85 (GM 2.94% / 3.47%) |
| AQI: 1.00 (AQ_t 0.31 / AQ_t-1 0.31) |
| SGI: 1.06 (Revenue 329b / 310b) |
| TATA: 0.00 (NI 2.55b - CFO 2.28b) / TA 81.7b) |
| Beneish M = -3.13 (Cap -4..+1) = AA |
As of June 04, 2026, the stock is trading at USD 263.64 with a total of 1,209,383 shares traded.
Over the past week, the price has changed by -1.26%,
over one month by -12.98%,
over three months by -28.86% and
over the past year by -8.89%.
Cencora has received a consensus analysts rating of 4.18. Therefore, it is recommended to buy COR.
- StrongBuy: 10
- Buy: 1
- Hold: 5
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 356.8 | 35.3% |
P/E Trailing = 20.6564
P/E Forward = 15.1976
P/S = 0.1594
P/B = 15.4247
P/EG = 0.6441
Revenue TTM = 329b USD
EBIT TTM = 3.06b USD
EBITDA TTM = 4.10b USD
Long Term Debt = 12.3b USD (from longTermDebt, last quarter)
Short Term Debt = 202.7m USD (from shortTermDebt, last quarter)
Debt = 12.4b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 10.1b USD (calculated: Debt 12.4b - CCE 2.24b)
Enterprise Value = 62.6b USD (52.4b + Debt 12.4b - CCE 2.24b)
Interest Coverage Ratio = 6.46 (Ebit TTM 3.06b / Interest Expense TTM 474.0m)
EV/FCF = 40.15x (Enterprise Value 62.6b / FCF TTM 1.56b)
FCF Yield = 2.49% (FCF TTM 1.56b / Enterprise Value 62.6b)
FCF Margin = 0.47% (FCF TTM 1.56b / Revenue TTM 329b)
Net Margin = 0.78% (Net Income TTM 2.55b / Revenue TTM 329b)
Gross Margin = 3.47% ((Revenue TTM 329b - Cost of Revenue TTM 317b) / Revenue TTM)
Gross Margin QoQ = 4.24% (prev 3.27%)
Tobins Q-Ratio = 0.77 (Enterprise Value 62.6b / Total Assets 81.7b)
Interest Expense / Debt = 3.83% (Interest Expense 474.0m / Debt 12.4b)
Taxrate = 27.21% (954.1m / 3.51b)
NOPAT = 2.23b (EBIT 3.06b * (1 - 27.21%))
Current Ratio = 0.95 (Total Current Assets 53.1b / Total Current Liabilities 56.1b)
Debt / Equity = 3.65 (Debt 12.4b / totalStockholderEquity, last quarter 3.40b)
Debt / EBITDA = 2.48 (Net Debt 10.1b / EBITDA 4.10b)
Debt / FCF = 6.51 (Net Debt 10.1b / FCF TTM 1.56b)
Total Stockholder Equity = 2.20b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.33% (Net Income 2.55b / Total Assets 81.7b)
RoE = 115.9% (Net Income TTM 2.55b / Total Stockholder Equity 2.20b)
RoCE = 21.18% (EBIT 3.06b / Capital Employed (Equity 2.20b + L.T.Debt 12.3b))
RoIC = 9.49% (NOPAT 2.23b / Invested Capital 23.5b)
WACC = 4.85% (E(52.4b)/V(64.8b) * Re(5.34%) + D(12.4b)/V(64.8b) * Rd(3.83%) * (1-Tc(0.27)))
Discount Rate = 5.34% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -80.28 | Cagr: -1.56%
[DCF] Terminal Value 73.10% ; FCFF base≈2.36b ; Y1≈2.07b ; Y5≈1.68b
[DCF] Fair Price = 86.08 (EV 26.9b - Net Debt 10.1b = Equity 16.7b / Shares 194.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 99.78 | EPS CAGR: 14.43% | SUE: 0.22 | # QB: 0
Revenue Correlation: 99.03 | Revenue CAGR: 10.17% | SUE: -2.19 | # QB: -1
EPS current Quarter (2026-06-30): EPS=4.37 | Chg30d=+0.92% | Revisions=+8% | Analysts=11
EPS current Year (2026-09-30): EPS=17.75 | Chg30d=+0.77% | Revisions=+40% | GrowthEPS=+10.9% | GrowthRev=+5.1%
EPS next Year (2027-09-30): EPS=19.78 | Chg30d=+0.86% | Revisions=+71% | GrowthEPS=+11.4% | GrowthRev=+6.3%
[Analyst] Revisions Ratio: +71%